Literature DB >> 9814557

A case of renal artery stenosis after transplantation: can losartan be more accurate than captopril renography?

D Fuster1, M Paz Marco, F J Setoain, F Oppenheimer, F Lomeña.   

Abstract

Hypertension is a common complication observed after renal transplantation. If the hypertension is of renovascular origin, transluminal angioplasty or surgery of the renal artery stenosis can lead help cure the hypertension. The blood pressure of a 31-year-old man who underwent renal transplantation 2 years earlier gradually increased. Arteriography showed stenosis (>80%) in the two branches of the renal artery. To help confirm the presence of renovascular hypertension, captopril renography was performed but showed no significant changes compared with baseline renography. Renography was performed again after losartan administration and showed impaired renal function. In this case, losartan renography was more useful than captopril in suggesting renovascular hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9814557     DOI: 10.1097/00003072-199811000-00001

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.

Authors:  W J Elliott
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

2.  Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing.

Authors:  Emel Ceylan Günay; M Halil Oztürk; Eser Lay Ergün; Bülent Altun; Bilge Volkan Salanci; Omer Uğur; Barbaros Cil; Baki Hekimoğlu; Biray Caner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-05       Impact factor: 9.236

3.  Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis.

Authors:  T L Johansen; A Kjaer
Journal:  BMC Nephrol       Date:  2001-05-17       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.